BI-1358894 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Borderline Personality Disorder (BPD). According to GlobalData, Phase II drugs for Borderline Personality Disorder (BPD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-1358894 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BI-1358894 overview

BI-1358894 is under development for the treatment of borderline personality disorder (psychosis), post-traumatic stress disorder (PTSD), major depressive disorder. It is administered by oral route as a film coated tablet. It acts by targeting short transient receptor potential channel 4 (TRPC4) and transient receptor potential channel 5 (TRPC5). It was also under development for cholecystokinin tetrapeptide (CCK-4) induced panic symptoms.

Boehringer Ingelheim International overview

Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for swine, ruminant, poultry, horses and pets among others. Boehringer is headquartered in Ingelheim, Rheinland-Pfalz, Germany.

For a complete picture of BI-1358894’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.